Concepedia

Author

Jonathon P. Orme

AstraZeneca (United Kingdom)

Also Known As

J Orme, J.P. Orme, Jonathon Orme, Jonathon P. Orme

30

Publications

3.2K

Citations

8

H-Index

40

Concepts

All Affiliations

AstraZeneca (United Kingdom)AstraZeneca (Singapore)Vanderbilt University
JP

About

Jonathon P. Orme is an author at AstraZeneca (United Kingdom) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

912

2

Natural Sciences

2

2

268

3

Biochemistry

2

2

268

4

Cell Biology

2

2

30

5

Health Sciences

1

1

19

Jonathon P. Orme

×

8

Publications

3.2K

Citations

8

H-Index

YearCitations

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Darren A.E. Cross, Susan Ashton, Serban Ghiorghiu,

Cancer Discovery

2014

2.2K

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

M. Raymond V. Finlay, Mark J. Anderton, Susan Ashton,

Journal of Medicinal Chemistry

2014

590

Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)

Richard A. Ward, Mark J. Anderton, Susan Ashton,

Journal of Medicinal Chemistry

2013

257

Protein–Ligand Crystal Structures Can Guide the Design of Selective Inhibitors of the FGFR Tyrosine Kinase

Richard A. Norman, Anne-Kathrin Schott, David Andrews,

Journal of Medicinal Chemistry

2012

46

Effects of drugs on ventricular fibrillation and ischaemic K+ loss in a model of ischaemia in perfused guinea-pig hearts in vitro

Michael Gwilt, C G Henderson, Jonathon P. Orme,

European Journal of Pharmacology

1992

35

Selective inhibition of protein secretion by abrogating receptor–coat interactions during ER export

Natalia Gómez‐Navarro, Julija Maldutyte, Kristina Poljak,

Proceedings of the National Academy of Sciences

2022

30

Abstract A109: AZD9291: an irreversible, potent and selective third generation tyrosine kinase inhibitor (TKI) targeting EGFR activating (EGFRm+) and resistance (T790M) mutations in advanced lung adenocarcinoma.

Darren A.E. Cross, Sue Ashton, Caroline A. Nebhan,

Molecular Cancer Therapeutics

2013

19

Examining Ligand-Based Stabilization of Proteins in Cells with MEK1 Kinase Inhibitors

Douglas S. Auld, Christopher A. Davis, Marta Jiménez,

Assay and Drug Development Technologies

2015

11

Page 1